Pub. Date : 1991 Jun 24
PMID : 1908183
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | This study examined the effect of gliclazide on tissue-type plasminogen activator (t-PA)-related fibrinolysis in 23 Type I diabetic patients without residual beta-cell function and 17 Type II diabetic patients initially treated with tolbutamide. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |
| 2 | This study examined the effect of gliclazide on tissue-type plasminogen activator (t-PA)-related fibrinolysis in 23 Type I diabetic patients without residual beta-cell function and 17 Type II diabetic patients initially treated with tolbutamide. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |
| 3 | In Type I diabetic patients, after 2-3 months of treatment with gliclazide, we observed a significant increase in plasma concentrations of total t-PA antigen that remained stable until discontinuation of the drug (p less than 0.0002), whereas the plasma concentrations of plasminogen activator inhibitor (PAI) did not change significantly during the study. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |
| 4 | Next, we investigated the possibility of gliclazide inducing t-PA-related fibrinolysis in a subset of Type II diabetics without detectable concentrations of t-PA during treatment with tolbutamide. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |
| 5 | The concentrations of active t-PA increased significantly 3 months after a change in treatment to gliclazide, and active t-PA again decreased in one patient to undetectable levels after 12 months with gliclazide. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |
| 6 | We conclude that gliclazide has the potential to exert extrametabolic non-insulin-mediated effects on t-PA-related fibrinolysis in diabetic patients. | Gliclazide | plasminogen activator, tissue type | Homo sapiens |